Morgan Stanley has recently raised Gilead Sciences Inc (GILD) stock rating, as announced on January 10, 2025, according to Finviz. Earlier, on December 10, 2024, BofA Securities had resumed the stock ...

Situated in Foster City, California, Gilead Sciences, Inc. (GILD) is a top biopharmaceutical company specializing in the ...

We recently published a list of 15 Best NASDAQ Dividend Stocks To Buy. In this article, we are going to take a look at where ...

GUANGDONG / LONDON, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Jade City, which is pioneering the tokenization of jade gemstones, today announced the launch of its Telegram mini-app ‘Flappy Jade’, inspired by ...

Jefferies analyst Michael Yee maintained a Buy rating on Gilead Sciences (GILD – Research Report) yesterday and set a price target of ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Lyell Immunopharma (LYEL – Research Report) ...

Shares of Gilead Sciences Inc. GILD rallied 1.52% to $92.38 Wednesday, on what proved to be an all-around great trading ...

Gilead Sciences (GILD) has reportedly settled a patent lawsuit with the federal government over its HIV drugs Truvada and ...

Gilead Sciences and the U.S. government have settled a billion-dollar patent dispute over Gilead's HIV prevention drugs ...

Gilead Sciences Inc (GILD) stock saw a modest uptick, ending the day at $91 which represents a slight increase of $1.06 or 1.18% from the prior close of $89.94. The stock opened at $90.59 and touched ...

The final trades of the day with CNBC’s Melissa Lee and the Fast Money traders. Judge Clears DOJ Release of Trump 2020 ...

Shares of Gilead Sciences Inc. GILD inched 0.07% higher to $89.94 Monday, on what proved to be an all-around positive trading ...